tak-676
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 29, 2020 (NCT04420884)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
STING1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04879849 | Phase 1 | Sep 9, 2021 | Takeda |
| NCT06062602 | Early Phase 1 (Phase 1) | Jul 26, 2021 | Presage Biosciences, Takeda |
| NCT04541108 | Early Phase 1 (Phase 1) | Nov 30, 2020 | Merck, Presage Biosciences, Takeda |
| NCT04420884 | Phase 1 | Jun 29, 2020 | Millennium Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 3 | 1 | 1 | 2020 |
| Presage Biosciences | For profit | 2 | 2 | 1 | 2020 |
| Merck | For profit | 1 | 0 | 1 | 2020 |
| Millennium Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1